
Pneumococcal infections - Pipeline Insight, 2024
Description
Pneumococcal infections - Pipeline Insight, 2024
DelveInsight’s, Pneumococcal infections - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pneumococcal infections: Overview
Pneumococcal infections: Overview Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections – these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections – these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.
""Pneumococcal infections - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.
- In February 2022, Affinivax and Astellas Pharma announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.
- This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
- ASP3772: Affinivax
Further product details are provided in the report……..
Pneumococcal infections: Therapeutic Assessment
This segment of the report provides insights about the Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pneumococcal infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
- Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
- Product Type
Pneumococcal infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.
Pneumococcal infections Report Insights
- Pneumococcal infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pneumococcal infections drugs?
- How many Pneumococcal infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pneumococcal infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Gangagen
- CanSino Biologics Inc.
- Pfizer
- Merck Sharp & Dohme
- EuBiologics
- Beijing Zhifei Lvzhu Biopharmaceutical
- SK Chemicals Co., Ltd.
- LG Life Sciences
- Astellas Pharma
- Affinivax
- ImmunoBiology
- Panacea Biotech
- SutroVax
- Vaxcyte
- Research programme: Pneumococcal infections therapeutics
- Pneumococcal vaccine
- PF 06842433
- V 116
- EuPCV15
- V 114
- ASP3772
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Pneumococcal vaccine conjugate 10-valent
- VAX 24
- VAX XP
Table of Contents
75 Pages
- Introduction
- Executive Summary
- Pneumococcal infections: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pneumococcal infections– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase III)
- Comparative Analysis
- Ceftobiprole medocaril: Basilea Pharmaceutica
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASP3772: Affinivax
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Pneumococcal vaccine conjugate 10-valent: Panacea Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Pneumococcal conjugate vaccine: EuBiologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- VAX XP: Vaxcyte
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pneumococcal infections Key Companies
- Pneumococcal infections Key Products
- Pneumococcal infections- Unmet Needs
- Pneumococcal infections- Market Drivers and Barriers
- Pneumococcal infections- Future Perspectives and Conclusion
- Pneumococcal infections Analyst Views
- Pneumococcal infections Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.